Literature DB >> 27812789

Serum Plant Sterols Associate with Gallstone Disease Independent of Weight Loss and Non-Alcoholic Fatty Liver Disease.

Pirjo Käkelä1, Ville Männistö2, Imre Ilves1, Maija Vaittinen3, Milla-Maria Tauriainen2, Matti Eskelinen1, Helena Gylling3,4, Hannu Paajanen1, Jussi Pihlajamäki5,6.   

Abstract

BACKGROUND: Gallstone disease (GD) has been associated with low serum levels of plant sterols. We evaluated the impact of laparoscopic Roux-en-Y gastric bypass (LRYGB) and non-alcoholic fatty liver disease (NAFLD) on the association of GD with low levels of serum plant sterols.
METHODS: Two hundred forty-two consecutive morbidly obese patients were recruited to this prospective study. Histological analysis of liver biopsy to diagnose NAFLD was performed. Bile sample was taken during the LRYGB. Associations of GD with serum non-cholesterol sterol to cholesterol ratios, measured using gas liquid chromatography and with mRNA expression of genes participating in the cholesterol, bile, and fatty acid metabolism in the liver, were analyzed.
RESULTS: Out of the 242 participants, 95 had GD. Lower weight (p = 0.002) and female sex (p = 0.0006) were associated with GD. Serum plant sterols, campesterol (p = 0.003), sitosterol (p = 0.002), and avenasterol (p = 0.015), were lower in patients with GD compared to those without GD. This association remained significant after adjustment for NAFLD, use of statin medication, and previous laparoscopic cholecystectomy (LCC). Levels of sitosterol (p = 0.001) and campesterol (p = 0.001) remained lower in obese individuals with GD also after obesity surgery. Liver mRNA expression of genes regulating cholesterol synthesis and bile metabolism was increased in individuals with GD.
CONCLUSIONS: Serum plant sterols were lower in patients with GD independent of NAFLD, history of LCC, use of statin medication, and weight loss after LRYGB. Low serum plant sterols in patients with GD suggest potentially inherited alterations in sterol absorption and biliary transport in subjects susceptible for GD.

Entities:  

Keywords:  Gallstones; Laparoscopic roux-en-Y gastric bypass; Obesity; Plant sterols; Statins; Weight loss

Mesh:

Substances:

Year:  2017        PMID: 27812789     DOI: 10.1007/s11695-016-2446-z

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  41 in total

1.  Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters.

Authors:  K E Berge; H Tian; G A Graf; L Yu; N V Grishin; J Schultz; P Kwiterovich; B Shan; R Barnes; H H Hobbs
Journal:  Science       Date:  2000-12-01       Impact factor: 47.728

Review 2.  New insights into the genetic regulation of intestinal cholesterol absorption.

Authors:  Frank Lammert; David Q-H Wang
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

Review 3.  Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol.

Authors:  Helen H Wang; Piero Portincasa; Ornella de Bari; Kristina J Liu; Gabriella Garruti; Brent A Neuschwander-Tetri; David Q-H Wang
Journal:  Eur J Clin Invest       Date:  2013-02-19       Impact factor: 4.686

4.  Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans.

Authors:  Jussi Pihlajamäki; Tiina Kuulasmaa; Dorota Kaminska; Marko Simonen; Vesa Kärjä; Sari Grönlund; Pirjo Käkelä; Matti Pääkkönen; Sakari Kainulainen; Kari Punnonen; Johanna Kuusisto; Helena Gylling; Markku Laakso
Journal:  J Hepatol       Date:  2011-10-23       Impact factor: 25.083

5.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

6.  Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity.

Authors:  Piia Simonen; Anna Kotronen; Maarit Hallikainen; Ksenia Sevastianova; Janne Makkonen; Antti Hakkarainen; Nina Lundbom; Tatu A Miettinen; Helena Gylling; Hannele Yki-Järvinen
Journal:  J Hepatol       Date:  2010-08-22       Impact factor: 25.083

Review 7.  Cholesterol gallstone disease.

Authors:  Piero Portincasa; Antonio Moschetta; Giuseppe Palasciano
Journal:  Lancet       Date:  2006-07-15       Impact factor: 79.321

8.  Cholesterol absorption decreases after Roux-en-Y gastric bypass but not after gastric banding.

Authors:  Jussi Pihlajamäki; Sari Grönlund; Marko Simonen; Pirjo Käkelä; Leena Moilanen; Matti Pääkkönen; Elina Pirinen; Marjukka Kolehmainen; Vesa Kärjä; Sakari Kainulainen; Matti Uusitupa; Esko Alhava; Tatu A Miettinen; Helena Gylling
Journal:  Metabolism       Date:  2009-12-16       Impact factor: 8.694

Review 9.  Nonalcoholic fatty liver disease and cholesterol gallstones: which comes first?

Authors:  Mohamed H Ahmed; Asif Ali
Journal:  Scand J Gastroenterol       Date:  2014-03-20       Impact factor: 2.423

10.  Relation between hepatic expression of ATP-binding cassette transporters G5 and G8 and biliary cholesterol secretion in mice.

Authors:  Astrid Kosters; Raoul J J M Frijters; Frank G Schaap; Edwin Vink; Torsten Plösch; Roelof Ottenhoff; Milan Jirsa; Iris M De Cuyper; Folkert Kuipers; Albert K Groen
Journal:  J Hepatol       Date:  2003-06       Impact factor: 25.083

View more
  1 in total

1.  Genome-wide association studies of metabolites in Finnish men identify disease-relevant loci.

Authors:  Xianyong Yin; Lap Sum Chan; Debraj Bose; Anne U Jackson; Peter VandeHaar; Adam E Locke; Christian Fuchsberger; Heather M Stringham; Ryan Welch; Ketian Yu; Lilian Fernandes Silva; Susan K Service; Daiwei Zhang; Emily C Hector; Erica Young; Liron Ganel; Indraniel Das; Haley Abel; Michael R Erdos; Lori L Bonnycastle; Johanna Kuusisto; Nathan O Stitziel; Ira M Hall; Gregory R Wagner; Jian Kang; Jean Morrison; Charles F Burant; Francis S Collins; Samuli Ripatti; Aarno Palotie; Nelson B Freimer; Karen L Mohlke; Laura J Scott; Xiaoquan Wen; Eric B Fauman; Markku Laakso; Michael Boehnke
Journal:  Nat Commun       Date:  2022-03-28       Impact factor: 14.919

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.